Abelacimab vs. Rivaroxaban: Reduced Bleeding Risk in Atrial Fibrillation Patients
Abelacimab Shows Promise for Atrial Fibrillation Treatment
Abelacimab (Anthos) has shown significant reductions in bleeding for patients with atrial fibrillation (AF), both on and off antiplatelet therapy (APT). This was demonstrated in the AZALEA-TIMI 71 trial (NCT04755283). Data presented at the American Heart Association 2024 Scientific Sessions confirms that abelacimab is a effective option for patients with AF who are at moderate-to-high risk of stroke.
Background on Atrial Fibrillation
Atrial fibrillation is the most common type of heart rhythm disorder affecting approximately 12.2 million people in the U.S. Individuals with AF face a fivefold increased risk of ischemic stroke, often resulting in serious consequences such as death or lasting neurological damage. While anticoagulants like rivaroxaban (Xarelto) help manage stroke risk, they can lead to increased bleeding.
Mechanism of Abelacimab
Abelacimab is an investigational monoclonal antibody that binds to factor XI in the blood clotting process. It prevents the activation of factor XIa, which is associated with harmful blood clots causing strokes or heart attacks, without disrupting normal clot formation needed for healing.
Trial Overview
The AZALEA-TIMI 71 trial involved over 1200 patients with AF or atrial flutter who needed long-term anticoagulation. Participants were randomly assigned to three groups: abelacimab 150 mg, abelacimab 90 mg, or rivaroxaban 20 mg. Abelacimab was administered monthly via injection, while rivaroxaban was given as a daily oral tablet.
Results
The study found that abelacimab reduced bleeding by 67% compared to rivaroxaban. Specifically, the bleeding incidence was 10.6% for rivaroxaban and only 3.5% for abelacimab at the 150 mg dose. Additionally, the risk of bleeding was higher when rivaroxaban was used with APT.
For patients taking APT, the bleeding rate with abelacimab was similar to those without APT (3.5% vs. 3.1%). When comparing abelacimab and rivaroxaban for those on APT, the risk difference was greater (7.1% vs. 4.6%).
Conclusion
Abelacimab may provide a safer alternative to traditional anticoagulants, especially for those needing both anticoagulation and antiplatelet therapy. Data from the study indicate it could be a beneficial option for patients at risk of bleeding complications.
Trial Information
- Trial Name: Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)
- ClinicalTrials.gov ID: NCT04755283
- Sponsor: Anthos Therapeutics Inc
- Estimated Completion Date: December 2025
References
- ClinicalTrials.gov Identifier: NCT04755283
- About atrial fibrillation. CDC.
- Gerlach A. Reduced bleeding with abelacimab could transform atrial fibrillation treatment. Pharmacy Times.
- Anthos therapeutics shares analysis from AZALEA-TIMI 71 study. Biospace.
- Kumbhani D. AZALEA-TIMI 71 study.
This new information highlights the potential of abelacimab to change treatment approaches for patients with atrial fibrillation, marking a significant development in cardiovascular care.